Efficacy of an Alpha-Blocker for the Treatment of Nonneurogenic Voiding Dysfunction in Women: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
- Author:
Young Suk LEE
1
;
Kyu Sung LEE
;
Myung Soo CHOO
;
Joon Chul KIM
;
Jeong Gu LEE
;
Ju Tae SEO
;
Jeong Zoo LEE
;
Ji Youl LEE
;
Seung June OH
;
Yong Gil NA
Author Information
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords: Adrenergic alpha-antagonists; Bladder outlet obstruction; Female; Urodynamics
- MeSH: Adrenergic alpha-Antagonists; Female; Humans; Lower Urinary Tract Symptoms; Nomograms; Receptors, Adrenergic, alpha-1; Urinary Bladder Neck Obstruction; Urodynamics
- From:International Neurourology Journal 2018;22(1):30-40
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: To evaluate the efficacy of an alpha-1 adrenergic receptor (α1-AR) blocker for the treatment of female voiding dysfunction (FVD) through a pressure-flow study. METHODS: This was a randomized, double-blind, placebo-controlled trial. Women aged ≥18 years with voiding symptoms, as defined by an American Urological Association symptom score (AUA-SS) ≥15 and a maximum flow rate (Qmax) < 15 mL/sec with a voided volume of >100 mL and/or a postvoid residual (PVR) volume >150 mL, were randomly allocated to either the alfuzosin or placebo group. After 8 weeks of treatment, changes in the AUA-SS, Bristol female lower urinary tract symptoms (BFLUTS) questionnaire, Qmax/PVR, and voiding diary were compared between groups. Patients’ satisfaction with the treatment was compared. Patients were categorized into 3 groups according to the Blaivas-Groutz bladder outlet obstruction (BOO) nomogram: none, mild, and moderate to severe. Subgroup comparisons were also made. RESULTS: Of a total of 187 women, 154 (79 alfuzosin, 75 placebo) were included in the analysis. After 8 weeks of treatment, the AUA-SS decreased by 7.0 in the alfuzosin group and by 8.0 in the placebo group. Changes in AUA-SS subscores, BFLUTS (except the I-sum), the voiding diary, and Qmax/PVR were not significantly different between groups. Approximately 54% of the alfuzosin group and 62% of the placebo group were satisfied with the treatment. No significant difference was observed between groups according to the presence or grade of BOO. CONCLUSIONS: Alfuzosin might not be more effective than placebo for treating FVD. The presence or the grade of BOO did not affect the results. A further study with sufficient power is needed to determine the efficacy of α1-AR blockers for the treatment of FVD.
